HUGH M. WILSON, M.D.; JAMES P. WILSON, M.D.; PAUL E. SLATON, M.D., F.A.C.P.; JOHN H. FOSTER, M.D.; GRANT W. LIDDLE, M.D., F.A.C.P.; JOHN W. HOLLIFIELD, M.D.
Saralasin, an angiotensin II antagonist, was infused into 49 patients with renal artery stenosis, 10 patients with essential hypertension and normal renal arteriograms, and five patients with "low-renin essential hypertension." Renal venous renin and differential renal function studies were used to assess the functional significance of arterial stenoses. "Response" to saralasin, evidenced by a fall in blood pressure during infusion, occurred in no patients with "low renin" hypertension and in only 20% of patients with normal renal arteriograms. In contrast, saralasin "response" occurred in more than 80% of patients with renal artery stenosis and lateralizing functional studies and in 100% of cases of "proven" renovascular hypertension (cure or improvement of hypertension after operative treatment). We suggest that saralasin infusion might be a valuable screening test for the recognition of renovascular hypertension.
WILSON HM, WILSON JP, SLATON PE, et al. Saralasin Infusion in the Recognition of Renovascular Hypertension. Ann Intern Med. 1977;87:36–42. doi: https://doi.org/10.7326/0003-4819-87-1-36
Download citation file:
Published: Ann Intern Med. 1977;87(1):36-42.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology, Prevention/Screening.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use